NCT02658019View on ClinicalTrials.gov

Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 6, 2016

Primary Completion Date

November 10, 2019

Study Completion Date

December 17, 2019

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Pembrolizumab

Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.

Trial Locations (1)

33136

University of Miami, Miami

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Lynn Feun, MD

OTHER

NCT02658019 - Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter